Iovance Biotherapeutics posts record $122M Q3 revenue with strong growth and promising cancer therapy trial results

Iovance Biotherapeutics reported a record third quarter 2026 revenue of approximately $122 million, marking an 80% increase year-over-year driven by strong demand for its cancer therapy Amtagvi. The company highlighted significant clinical progress, including a 24.6% objective response rate in non-squamous metastatic non-small-cell lung cancer and a 55.6% response rate in certain sarcoma patients, with ongoing trials supporting future regulatory submissions. Iovance remains on track to meet its full-year revenue guidance of $410 to $420 million and is expanding its authorized treatment center network internationally. These developments position Iovance as a leader in tumor infiltrating lymphocyte therapies with a robust pipeline and global market expansion plans.

Following Iovance Biotherapeutics' announcement of record third quarter revenue, its stock price rose by 5.75% on the day. On Pluang, IOVA trades at USD 9.20 as of Nov 05, 2026 19:11 WIB, with a market cap of $3.95 billion. The stock shows balanced investor interest with 52% buy orders and 48% sell orders, reflecting active trading around this health sector name.